A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Trial Profile

A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Hydroxyprogesterone (Primary) ; Hydroxyprogesterone (Primary)
  • Indications Preterm labour
  • Focus Therapeutic Use
  • Sponsors AMAG Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top